Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons

Vaccine

Volumn 17, Issue 2, 1999, Pages 99-104

  Minutello, M ^a   Senatore, F ^a   Cecchinelli, G ^b   Bianchi, M ^b   Andreani, T ^b   Podda, A ^a   Crovari, P ^c  

^a CHIRON VACCINES   (Italy)

^b Centro Medicina di Gruppo   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

Adjuvant; Influenza; Vaccine

Indexed keywords

IMMUNOLOGICAL ADJUVANT; INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINE; POLYSORBATE; SORBITAN; SQUALENE; UNCLASSIFIED DRUG;

AGED; ANTIBODY RESPONSE; ARTICLE; CHILL; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELDERLY CARE; EMULSION; ERYTHEMA; HEMAGGLUTINATION INHIBITION; HUMAN; IMMUNOGENICITY; INFLUENZA VACCINATION; INTRAMUSCULAR DRUG ADMINISTRATION; MALAISE; NORMAL HUMAN; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

ADJUVANTS, IMMUNOLOGIC; AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; INFLUENZA VACCINES; MALE; ORTHOMYXOVIRIDAE; POLYSORBATES; PROSPECTIVE STUDIES; SAFETY; SQUALENE; VACCINES, INACTIVATED;

EID: 0032889660     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00185-6     Document Type: Article

References (16)

1. Barker W.H. Excess pneumonia and influenza associated hospitalization during influenza epidemics in the United States, 1970-78. Am. J. Pub. Hlth. 76:1986;761-765.
2. Barker W.H., Mullooly J.P. Impact of epidemic type A influenza in a defined adult population. Am. J. Epidemiol. 112:1980;798-811.
3. Glezen WP, Six HR, Frank AL, Taber LH, Perrotta DM, Decker M. Impact of epidemics upon communities and families. In: Options for the Control of Influenza (Eds Kendal AP.and Patriarca PA). Alan R. Liss, New York, 1986, pp. 63-73.
4. Sprenger MJW, Beyer WEP, Kempen BM, Mulder PGH, Masurel N. Risk factors for influenza mortality? In: Options for the Control of Influenza II (Eds Hannoun C, Kendal AP, Klenk HD and Ruben FL). Excerpta Medica, New York, 1993, pp. 15-23.
5. Arden NH, Patriarca PA, Kendal AP. Experiences in the use and efficacy of inactivated influenza vaccine in nursing homes. In: Options for the Control of Influenza (Eds Kendal AP and Patriarca PA). Alan R. Liss, New York, 1986, pp. 155-168.
6. Barker WH, Mullooly JP. Effectiveness of inactivated influenza vaccine among non-institutionalized elderly persons. In: Options for the Control of Influenza (Eds Kendal AP and Patriarca PA). Alan R. Liss, New York, 1986, pp. 169-182.
7. Advisory Committee on Immunization Practices. Prevention and Control of Influenza: Part 1, Vaccines Recommendations of the ACIP, 1997, 46 (RR-9), pp. 1-25.
8. Palache AM. Dose-comparative serological studies: critical evaluation of the parameters to assess the antibody response to influenza vaccination. In: Influenza Vaccination. The Effect of Dose and Age on the Antibody Response (Ed. Palache AM). Broos Amsterdam, Amsterdam, The Netherlands, 1991, Chap. 4. pp. 81-86.
9. Van Nest GA, Steimer KS, Haigwood NL, Burke RL, Ott G. Advanced adjuvant formulations for use with recombinant subunit vaccines. In: Vaccines 92. (Eds Brown F, Chanock RH, Ginsberg HS and Lerner RA.). Cold Spring Harbor Laboratory Press, Cold Spring Harbor, 1992, pp. 57-62.
10. Ott G, Barchfeld GL, Chernoff D, Radhakrishnan R, van Hoogevest P, Van Nest G. MF59: design and evaluation of a safe and potent adjuvant for human vaccines. In: Vaccine Design: The Subunit and Adjuvant Approach (Eds Powell MF and Newman MJ). Plenum Press, New York, 1995, Chap. 10. pp. 227-296.
11. Kahn J.O., Sinangil F., Baenziger J.et al. Clinical and immunologic responses to Human Immunodeficiency Virus (HIV) Type 1 SF2 gp 120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoil phosphatidylethanolamine in non-HIV-infected human volunteers. J. Infect. Dis. 170:1994;1288-1291.
12. World Health Organization Recommended composition of influenza virus vaccines for use in the 1992-1993 season. Weekly Epidemiol. Rec. 67(77):1992;2.
13. World Health Organization Recommended composition of influenza virus vaccines for use in the 1993-1994 season. Weekly Epidemiol. Rec. 68(9):1993;57.
14. World Health Organization Recommended composition of influenza virus vaccines for use in the 1993-1994 season. Weekly Epidemiol. Rec. 69(8):1994;53.
15. CPMP Good clinical practice for trials on medicinal products in the European Community. III/3976/88-EN Final. Pharmacol. Toxicol. 67:1990;361-372.
16. Dowdle WN, Kendal AP, Noble GR. Influenza viruses. In: Diagnostic Procedures for Viral, Rickettsial and Chlamydial Infections (Eds Lenette EH and Schmidt NJ), 5th ed. American Public Health Association, Washington, DC, 1979, pp. 603-605.